News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Natalie S. Callander, MD, University of Washington Carbone Cancer Center

Articles by Natalie S. Callander, MD, University of Washington Carbone Cancer Center

BCMA-Targeted Therapies in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

MRD Monitoring in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

The Role of Transplant in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Treating Transplant-Eligible and -Ineligible MM

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Transplant-Ineligible Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Tolerability of Triplet Therapy in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Frontline Triplet Therapies in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Trending on OncLive

FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies

As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology

GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care

Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies

Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer